We present a case of 71-year-old man…who was initially diagnosed with CML....The cytogenetic analysis revealed the presence of an uncommon three-way translocation 46,XY,t(4;9;22)(q21;q34;q11) in all metaphases obtained from the bone marrow, confirmed with positive dual fusion FISH probe for t(9;22)BCR/ABL. Treatment with tyrosine kinase inhibitor (TKI), nilotinib (300mg bid), was started and the patient achieved a complete hematologic response and at 3 months – complete cytogenetic response with normal bone marrow karyotype and early molecular response. MM was diagnosed, in addition to CML. Chemotherapy with weekly bortezomib, cyclophosphamide and dexamethasone was preferred considering the risk of drug interactions and pancytopenia when combined with nilotinib for CML. The patient achieved complete response with 6 courses of chemotherapy for MM, deep molecular response (DMR) of CML at the first year of TKI therapy. This is for the first time that CML patient with three-way translocation t(4;9;22)(q21;q34;q11) is diagnosed with MM. Our case demonstrates that nilotinib combined with certain myeloma therapy can be considered safe and efficient in a case of CML and MM comorbidity.